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ABSTRACT
Objectives To present methods and baseline results
for an online screening tool to identify increased risk for
Parkinson’s disease (PD) in the UK population.
Methods Risk estimates for future PD were derived
from the results of a systematic review of risk factors and
early features of PD. Participants aged 60–80 years
without PD were recruited by self-referral. They
completed an online survey (including family history,
non-motor symptoms and lifestyle factors), a keyboard-
tapping task and the University of Pennsylvania Smell
Identiﬁcation Test. Risk scores were calculated based on
survey answers. Preliminary support for the validity of
this algorithm was assessed by comparing those
estimated to be higher risk for PD with those at lower
risk using proxies, including smell loss, REM-sleep
behaviour disorder and reduced tapping speed, and by
assessing associations in the whole group.
Results 1324 eligible participants completed the survey
and 1146 undertook the keyboard-tapping task. Smell
tests were sent to 1065 participants. Comparing the 100
highest-risk participants and 100 lowest-risk participants,
median University of Pennsylvania Smell Identiﬁcation
Test scores were 30/40 versus 33/40 (p<0.001), mean
number of key taps in 30 s were 55 versus 58
(p=0.045), and 24% versus 10% scored above cut-off
for REM-sleep behaviour disorder (p=0.008). Regression
analyses showed increasing risk scores were associated
with worse scores in the three proxies across the whole
group (p≤0.001).
Conclusions PREDICT-PD is the ﬁrst study to
systematically combine risk factors for PD in the general
population. Validity to predict risk of PD will be tested
through longitudinal follow-up of incident PD diagnosis.
INTRODUCTION
Parkinson’s disease (PD) affects 1% of individuals
over the age of 60 years.1 2 The clinical diagnosis
of PD is often made late and current treatments
address symptoms and not the underlying disease
process.3 A key priority in PD is early detection
and treatment with drugs that have disease-
modifying effects.4
Many initiatives have been set up to identify
individuals or groups at risk of PD.5 These include
longitudinal studies in groups that have an excess
background risk of PD and studies using proposed
screening tests to delineate risk.6–10 Due to the cost
and availability of these tests, a non-invasive,
widely available and inexpensive method to select
groups for further investigation would be desirable.
A large number of historical risk factors and
early non-motor features of PD have been reported
from observational studies. Recently, our group
reported a systematic exploration of factors that
can be screened for in a primary care setting.11 In
parallel to this, we initiated the PREDICT-PD
study; an internet-based study in the UK general
population to identify a group at higher risk of PD,
using an algorithm that estimates the possible risk
of developing PD from information that can be col-
lected using online tools. We describe here the
development of the preliminary algorithm derived
from the results from the systematic review of pub-
lished literature.11 The performance of this prelim-
inary algorithm was assessed by comparing the
occurrence of a combination of proxies for future
PD, including three of the strongest individual
markers of increased PD risk (smell loss, report of
REM sleep-behaviour disorder (RBD) and ﬁnger-
tapping speed), in those estimated to be at higher
risk of PD alongside those estimated to be at lower
risk. Conﬁrmation of validity will be tested in the
longitudinal follow-up of study participants, using
incident PD diagnosis as the outcome.
METHODS
The study was approved by Central London
Research Committee 3 (reference number 10/
H0716/85). Participants were recruited via the
study website following a limited advertising cam-
paign on local radio and in magazines with an
older readership, and by email to members of the
Parkinson’s UK charity. Participants submitted an
online consent form before passing to the secure
test area. Inclusion criteria in this phase were resi-
dency in the UK and age 60–80 years. Exclusion
criteria were pre-existing PD, movement disorder,
stroke, motor neuron disease, dementia or drug
usage known to be associated with iatrogenic
Parkinsonism.
Participants completed a survey with demo-
graphic questions and items related to early non-
motor features and risk factors for PD, which
incorporated validated questionnaires, that is, the
Hospital Anxiety Depression Scale, the RBD
Screening Questionnaire (RBDSQ), and a number
of individual questions that had been used in good
quality observational studies that previously
reported risk factors for PD.12 13 For the RBDSQ,
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we used a cut-off score of ≥5, which has previously been shown
to have a sensitivity of 96% and speciﬁcity of 56% for diagnosis
of RBD conﬁrmed by polysomnography.13
The overall survey length was 56 items and it took approxi-
mately 20 min to complete, based on prior testing by members
of the research team and 10 independent healthy volunteers
aged 60–80 years, whose data were not included in the results.
Immediately after the survey, participants were invited to
undertake a keyboard tapping task, the bradykinesia akinesia
incoordination test (BRAIN test), which is used to assess upper
limb motor function.14 15 The BRAIN test has recently been
redeveloped to run in all internet browser software and has been
validated in patients with PD and controls (manuscript in prepar-
ation, permission granted by AJN 2013). Participants use the
index ﬁnger of a single hand to alternately strike the ‘S’ and ‘;’
keys on a standard computer keyboard, as fast and accurately as
possible. The test is repeated for the other hand. The BRAIN test
reports four variables calculated from key taps; (a) kinesia score
(KS30), the number of key taps in 30 s; (b) akinesia time (AT30),
the mean dwell time on each key in milliseconds (ms); (c) dysme-
tria score (DS30), a weighted index using the number of incor-
rectly hit keys scored in a target fashion; and (d) arrhythmia
score (AS30), the variance of the time interval in milliseconds
between keystrokes. Of these KS30 is the most sensitive param-
eter for diagnosis of PD and determining PD severity.14 The
BRAIN test can be accessed at http://www.predictpd.com/
braintest and applications to use this can be directed to AJN via
the same web link.
Participants were also sent the US version of the University of
Pennsylvania Smell Identiﬁcation Test (UPSIT) via post. The
UPSIT is a 40-item scratch and sniff smell test (composed of
four booklets, each with 10 test pages) that has been used exten-
sively in the investigation of smell disturbance in neurological
disease.16 In line with the ongoing Parkinson’s At-Risk Study,
which uses smell loss to identify individuals at risk of future PD,
we used the lower 15th centile of UPSIT scores as the cut-off to
denote hyposmia.6 The answers were entered on the study
website by most participants. A minority (n=155) returned
results completed in the test booklets only.
Analysis
Based on the results of our recent systematic review, which pro-
vided risk estimates for each early non-motor feature or risk
factor signiﬁcantly associated with altered risk of PD, we devel-
oped a preliminary algorithm to provide PD risk scores for each
participant.11 In this algorithm we included age, gender,
smoking status, family history of PD, coffee use, alcohol use,
hypertension, non-steroidal anti-inﬂammatory drug use, calcium
channel blocker use, β blocker use, constipation, previous head
injury, anxiety or depression and erectile dysfunction (in men
only). Most factors were sought in binary terms (ie, presence or
absence) except for bowel movement frequency (seven possible
answers for frequency with a cut-off of less than one movement
per day denoting low frequency), erectile dysfunction (three
options with ‘poor’ or ‘fair’ indicating dysfunction) and mood
(a cut-off score of 8 or above in either the anxiety or depression
components of the Hospital Anxiety Depression Scale question-
naire denoting mild forms of these disorders). In order to keep
the survey simple, pesticide exposures, proxies for organochem-
ical exposure and more complicated factors were not included.
Any subject that reported a neurological diagnosis listed in the
exclusion criteria was removed from the analysis.
Importantly, we did not include smell loss and RBD, which
are reported to be two of the strongest estimated risk factors for
future PD (along with ﬁnger tapping in selected risk groups8).
These were instead used as outcome measures or proxies for
preliminary validation of the basic algorithm (see below). For
each individual, the age-related risk (expressed as an odds) of
developing PD was determined based on results from the
Physician’s Health Study.1 The equation determined from these
data was:
Odds of PD ¼ 1 : 28:53049þ 73:67057e(0:165308(age60))
As these data were from an all-male cohort, and prevalence of
PD is approximately 1.5 times greater in men, the age risk for
women was reduced accordingly.17 An individual’s risk was
increased or decreased by each of the above factors according to
the strength of association with PD reported in the systematic
review.11 For example a male, current smoker with a 1:100
age-related risk of developing PD was calculated to have a risk
of 0.44×1:100=1:227. If that individual also had a family
history of PD their risk was calculated as 4.45×1:227=1:51.
The risks for all participants were ranked and the 100 with the
highest risk and 100 with the lowest risk scores were identiﬁed.
The preliminary validity of this recruitment and risk estima-
tion method was tested by comparing three of the potentially
strongest individual markers of increased PD risk (smell loss,
RBD and ﬁnger-tapping speed) between the 100 participants
calculated to be at highest and lowest risk. Several lines of evi-
dence (including pathology and imaging) suggest that loss of
smell may be a sensitive (albeit not speciﬁc) predictor of
PD.9 10 18–22 RBD is rare in the general population but its pres-
ence carries a high risk of conversion to PD in longitudinal
cohort studies making it relatively speciﬁc albeit not
sensitive.23–25 Bradykinesia is a core feature of PD and subtle
motor signs can precede the diagnosis of PD by several years,
suggesting that ﬁnger tapping may be a sensitive early feature of
PD risk.8 26 27
We hypothesised that if the preliminary algorithm were suc-
cessful, those in the higher-risk group would have signiﬁcantly
lower UPSIT scores, higher rates of RBD and slower tapping
speeds than the lower-risk group. Conﬁrmatory ﬁndings would
suggest that the algorithm was enriching a population for
increased risk of PD.
Statistics
UPSIT, RBDSQ and BRAIN test scores between the 100 highest
and 100 lowest risk individuals according to the algorithm were
compared using t tests and described using means, where data
were normally distributed. Where data did not follow a normal
distribution, medians and the Mann-Whitney U test were used.
Comparisons for data split into categories were made using the
χ2 test. The relationships between UPSIT, BRAIN and RBDSQ
scores with predicted risk of PD in the whole dataset were also
examined using median, linear and Poisson regressions, respect-
ively. All analyses were performed using Stata V.10.
RESULTS
Figure 1 shows the ﬂow of participants in the study. Of the
1463 individuals that registered, consented and completed the
survey, 139 met exclusion criteria in light of their past medical
history (including existing PD and other neurological diagno-
ses), country of residence or age. This left 1324 eligible survey
responders, of whom 1146 undertook the BRAIN (keyboard
tapping) test and submitted results for at least one hand. Upon
analysing these data, 139 BRAIN test results were deemed
unsuitable for inclusion leaving 1007 results for the ﬁnal
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analysis. Most excluded BRAIN test results were because of
implausibly low (<15) or implausibly high (>100) KS30 scores
since they indicated that the test instructions had been misun-
derstood or, that the test was performed using two hands
together rather than separately. Other cases were excluded if
their dysmetria score was greater than or equal to 1.5, indicating
at least half the keystrokes were to the wrong key. These cut-offs
were assigned based on previous BRAIN test data (manuscript in
preparation). The funding enabled 1065 participants to be sent
smell tests. Results were received for 908 of these either via the
website or as a hard copy, of which 22 were incomplete and
886 were suitable for inclusion in ﬁnal analysis. Thus 75.9% of
eligible individuals who successfully undertook the survey com-
pleted a suitable BRAIN test, and 83.1% of people that were
sent a smell test completed it and submitted results that could
be used in the analysis.
The prevalence of factors that contributed to individuals’ pre-
dicted risk of PD is presented for the whole group, for the 100
individuals with the highest and for the 100 with the lowest pre-
dicted risks in table 1. The results for the three proxies (UPSIT,
RBDSQ and BRAIN test scores) were also determined in these
three groups (table 2). Additional demographic data that did not
contribute to the risk score including occupation, ethnicity and
education are listed in the online supplementary material
(table 3), along with further analyses of associations between
risk factors (see online supplementary table 4).
In the 100 individuals with highest estimated risk as calculated
using the algorithm, the median UPSIT score was 30 (IQR 28–
33) and in the 100 with the lowest estimated risk it was 33 (IQR
31–36; p<0.001). Using the lower 15th centile as a cut-off corre-
sponded to an UPSIT score of 27.6 Six per cent (4/65) of the
lower-risk and 20% (13/65) of the higher-risk participants had
an UPSIT score below 27 (p=0.019). We did not use age-speciﬁc
and gender-speciﬁc 15th centile cut-offs for the UPSIT since age
and gender were factors included in the algorithm. The median
RBDSQ in both the lowest and highest risk groups was two (IQR
0–3 and 1–4, respectively), but the sum of the ranks was larger in
the higher-risk group than in the lower-risk group (p=0.016).
Using the RBDSQ cut-off score of ≥5, more people had RBD in
the higher-risk group compared with the lower-risk group (24%
vs 10%, p=0.008).13 For the BRAIN test, the mean KS30 scores
in the higher-risk and lower-risk groups were 54.7 and 58.1,
respectively (p=0.045). There were no signiﬁcant differences in
the other three BRAIN test variables (data not shown). Further
analyses using only subjects that had complete outcome measure
data sets were also undertaken and gave similar signiﬁcant ﬁnd-
ings (see online supplementary table 5).
UPSIT, RBDSQ and KS30 scores were plotted against esti-
mated risk of PD in all participants (ﬁgure 2). Estimated risk of
PD as calculated by the algorithm doubled with a decrease of
UPSIT scores by 0.53 points (95% CI 0.29 to 0.77, p<0.001),
an increase of RBDSQ scores by 8.0% (95% CI 4.5% to 11.7%,
p<0.001) and a decrease of KS30 scores by 0.75 points (95%
CI 0.32 to 1.19, p=0.001).
DISCUSSION
This is one of largest cross-sectional studies to date examining
methods to identify a group of individuals with risk factors for
Figure 1 Flow of participants in the study.
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developing PD. The methodology is based on a comprehensive
systematic review of the literature on early features and risk
factors of PD that can be identiﬁed through history taking, and
on calculating estimates of risk through combination of these
factors.11 We found conﬁrmation for our hypotheses that those
deemed to be at higher risk of PD would have poorer smell
sense, increased rates of RBD and slower ﬁnger tapping speed,
when compared with the lower-risk group. Ultimately, conﬁrm-
ation of the validity of this algorithm requires recording an
increased rate of incident PD in the higher-risk group, and this
information will only become available during longitudinal
follow-up.
Internet-based recruitment allowed us to gather a large
sample size without high expenditure; the participants were
recruited relatively easily, and completion rates for individual
stages of the study, and the study as a whole, were high. The
penetration of the internet has increased over the last decade,
including use in the over 60 years age group.28 This means that
similar research can be undertaken via the internet as a means
of accessing large populations, with frequent retesting and rela-
tive convenience, while making dramatic savings to cost, when
compared with traditional longitudinal studies. The longitudinal
component of this study will also seek to incorporate additional
risk factors in light of new research and data collected within
the study, including the role of occupation, self-reported motor
symptoms and other markers of bowel function (eg, laxative use
and stool hardness). Our methods relied on self-recruitment,
which introduces potential for recruitment bias, and also on
self-reporting without conﬁrmation of results (except smell
testing and tapping speed). This method, even with future modi-
ﬁcations, is therefore unlikely, on its own, to be a reliable
measure of prediagnostic PD. However, the purpose of this
ongoing longitudinal study is to provide a mechanism by which
a group at increased risk can be identiﬁed from the general
population for inclusion in more detailed studies that will be
more demanding in terms of time, resources and effort by parti-
cipants and researchers, including those using imaging and
laboratory biomarkers (ﬁgure 3).
Our results are in keeping with recent reports of combined
screening measures to predict future PD in other longitudinal
studies of prediagnostic PD.5 We found a signiﬁcant difference
in the average UPSIT score between the higher-risk and lower-
Table 1 Prevalence of factors that contributed towards the risk score
Factor All participants (n=1324) 100 with highest risk 100 with lowest risk RR/OR from systematic review11
Male 519 (39%) 83 11 See methods
Age in years (median, IQR) 67 (64–71) 70 (67–74) 63 (62–65) See methods
Smoker
Current 51 (4%) 2 24 0.44
Former 523 (39%) 45 41 0.78
Never 750 (57%) 53 35 1.00
Family history of PD 262 (20%) 58 0 4.45
Drink coffee 1187 (90%) 82 99 0.67
Drink alcohol 1138 (86%) 87 87 0.90
Hypertension 348 (26%) 29 42 0.74
NSAID use 83 (6%) 2 15 0.83
CCB use 155 (12%) 14 14 0.90
β Blocker use 103 (8%) 14 5 1.28
Constipation 82 (6%) 24 1 2.34
Head injury 361 (27%) 52 6 1.58
Depression/anxiety 254 (19%) 44 1 1.86
Erectile dysfunction (men) 181 (35%) 72 0 3.80
CCB, calcium channel blockers; NSAID, non-steroidal anti-inflammatory drug; PD, Parkinson’s disease.
Table 2 UPSIT, RBDSQ and KS30 scores in all participants and those with the highest and lowest predicted risks of Parkinson’s disease
Outcome All participants 100 with highest risk 100 with lowest risk p Value highest vs lowest risk
UPSIT
N 886 65 65 –
Median (IQR) 32 (29–34) 30 (28–33) 33 (31–36) <0.001
N (%)≤27 135 (15%) 13 (20%) 4 (6%) 0.019
RBDSQ
N 1324 100 100 –
Median (IQR) 2 (1–3) 2 (1–4) 2 (0–3) 0.016
N (%)≥5 203 (15%) 24 (24%) 10 (10%) 0.008
KS30
N 1007 78 77
Mean (95% CI) 56.5 (55.9 to 57.2) 54.7 (52.6 to 56.7) 58.1 (55.4 to 60.9) 0.045
KS30, Kinesia score (number of key taps in 30 s); RBDSQ, REM sleep behaviour disorder screening questionnaire; UPSIT, University of Pennsylvania Smell Identification Test.
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Figure 2 (a) UPSIT, (b) RBDSQ and (c) KS30 scores plotted against estimated risk of PD with regression lines.
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risk groups identiﬁed through the algorithm, and a signiﬁcant
difference in proportion in the higher-risk and lower-risk group
that had a score below the lower 15th centile cut-off of 27.
Analogous results were recently reported in the Parkinson’s
At-Risk Study where patients with hyposmia were signiﬁcantly
more likely to report non-motor features, including anxiety and
depression, constipation and rapid eye movement sleep behav-
iour disorder symptoms, and to report changes in motor func-
tion.6 RBD, as suggested by an RBDSQ score of ≥5, was
signiﬁcantly more frequent in the high-risk than the low-risk
group, and tapping speed was signiﬁcantly lower in the high-risk
group, indicating that at least some of the individuals in the
high-risk group may be in the very earliest stages of motor
impairment. Subtle changes in movement control have previ-
ously been reported in video footage of the footballer Ray
Kennedy several years before onset of diagnosed PD and in
patients with conﬁrmed RBD.8 27 Of note also is the fact that
the scores for all three proxies for PD were signiﬁcantly worse
with increasing predicted risk of PD across all participants.
Individually, none of these three outcomes is speciﬁc and sensi-
tive for early PD. However, evidence from pathological, epi-
demiological and imaging studies suggest that each of them is
associated with an increased risk of PD, and consistent correl-
ation of these markers with higher risk as deﬁned by the algo-
rithm is in keeping with this algorithm being able to identify a
higher-risk group.29–31 Taken together, these results all indicate
that this evidence-based algorithm has the potential to be a
useful tool to identify groups at higher risk of future PD for
inclusion in studies to identify biomarkers for early PD.
Study limitations
First, many of the participants volunteered following advertising
by a Parkinson’s charity. Therefore many had a family history of
PD and may have been fearful about their own risk of the
disease. This is a measurable bias in part and increases the likeli-
hood of ﬁnding those at high risk. Second, in using proxies for
future PD risk, it is unknown currently what proportion of
those that are at higher risk will go on to develop PD. The
numbers are likely to be small given the number of participants
in the study to date and the incidence of PD in the general
population. Nonetheless, the conversion of individuals in the
higher-risk group and not the lower-risk group to clinically
established PD would offer strong evidence of the predictive
nature of the algorithm. Third, for this analysis it was assumed
the predictors are independent, and this is unlikely to be the
case. Although the ﬁgures from the systematic review were
adjusted for confounders, further analysis showed some associ-
ation between factors (see online supplementary table 4). The
simple additive model we are using may therefore not fully rep-
licate the early stages of the disease. Currently there are insufﬁ-
cient data in the literature to account for robust interactions and
one aim of the longitudinal study is to modify the results based
on emerging prospective data. Fourth, RBD and other reports
of clinical features were not conﬁrmed using polysomnography
(although the RBDSQ has been validated against polysomnogra-
phy13) or other objective tests. This is likely to reduce the accur-
acy of these predictive factors but the purpose of this
methodology is to be easily available and non-invasive, which
objective conﬁrmatory tests often are not. Fifth, due to the
design of the study, there is an additional bias in that we have
identiﬁed participants that are English-speaking and computer
literate (data in online supplementary table 3 showed that the
majority of participants were well educated and most were
Caucasian). Finally, in order to test the initial validity of our
approach we adopted a conservative method excluding the most
promising risk factors of smell loss, RBD and tapping speed
from the algorithm and used these as proxies to evaluate its per-
formance. Our results were signiﬁcant despite their exclusion
and it is likely that subsequent inclusion of smell loss, RBD and
tapping speed will improve the performance of the algorithm.
However, doing this will require estimation of the magnitude of
risk conveyed by each since absolute data are currently not avail-
able in the literature. Our hypotheses will be tested further
when longitudinal results are available from this study in its
Figure 3 Schematic indicating how a screening process might channel into detailed biomarker and risk-determination studies in groups identiﬁed
as being higher risk than the background population.
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current and expanded form, which will lead to modiﬁcations of
this preliminary algorithm.
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